Strides Pharma Science Share Price Live

History

Strides Pharma Science Ltd was incorporated, originally under the name ‘Strides Arcolab Ltd’, on June 28th, 1990. In 2002-03, the company signed an MoU with Ribbon SRL Italy to set up a joint venture to manufacture and market Cephalosporin formulations for regulated markets. The company transferred its Contract Research and Manufacturing Division (CRAM) to the wholly owned subsidiary, Strides Research & Specialty Chemicals Ltd, effective from April 1, 2002. In 2005, the company established its new technology centre named STAR-Strides Technology and Research. They also expanded their Anti TB Facility at KRS Gardens, Bengaluru.

In 2008, the company completed a series of divestments and acquisitions and rearranged its business into 3 specific business segments, namely Manufacturing and R&D, International Front-ended Business-Generics and Brands and Nutraceuticals Business. In April 2009, they announced a major reorganisation of their business whereby they split their operations into 3 separate entities, namely Specialty Pharmaceuticals, Pharmaceuticals & R&D.

In December 2012, the company with its subsidiary Agila Specialties Private Ltd collaborated with Eli Lilly to expand the delivery of its cancer medicines in emerging markets. As a part of this arrangement, Lilly in-licensed a portfolio of high-quality, branded generic injectable and oral cancer medicines from Agila Specialties, the specialities division of Strides. 

In FY 2018, the company exited from the India Brand Business. In 2018-19, the R&D operations of the company remained on track with 21 ANDA filings as against the 20-25 ANDA filings planned for the year. The company also received 15 product approvals in FY 2019. This included the PARA IV approvals for Cinacalcet and Milnacipran Hydrochloride.

Business Segments

As per accounting terms, the company has two business segments reported, i.e. pharmaceutical and bio-pharmaceutical businesses. In terms of the diseases cured, the company’s institutional business is divided into the following categories:

1. AIDS – The focus of Strides is on the production and supply of newer anti-retroviral drugs that are difficult to manufacture, including pediatric dispersible formulations, new fixed-dose molecules which Strides accesses through license agreements with Gilead, Vive Healthcare, MPP, among others.
2. TB or Tuberculosis – Strides has its own state-of-the-art anti-TB drug facility formulating the second-line TB drug.
3. Malaria – Strides has begun the supply of WHO Pre-Qualified Artemether and Lumefantrine (AL) Tablets, and also AL Dispersible tablets for pediatric use. It has ERP approval for AL 80/480 and Artesunate Suppositories caps.
4. Hepatitis – Strides has launched “Sofosbuvir and it’s combination drugs” in Africa, South East Asia, CIS and Latam countries for Hepatitis C treatment. This represents a paradigm shift in the existing Hepatitis C cure.

Subsidiaries

As of March 31, 2023, the company has 43 subsidiaries, including:

1. Altima Innovations Inc. – It is a wholly owned subsidiary engaged in trading in pharmaceutical products in the USA.
2. Generic Partners UK Ltd. – It is a wholly owned subsidiary that supplies and distributes generic pharmaceutical products in the UK.
3. Pharmapar Inc. – It is a wholly owned subsidiary that trades in pharmaceutical products in Canada.
4. Strides Pharma Global (UK) Ltd. – It is an Investment Holding company in the UK that is 100% owned by Strides Pharma Science.

Key Personnel

Mr Arun Kumar, Executive Chairperson and Managing Director

Mr Kumar is the Company’s Founder and also the Promoter Director. He is a first-generation entrepreneur with an impressive track record. He founded the company in 1990 and has since led it in establishing a global reputation along with a differentiated business model.

Corporate Actions

The company has not performed any major corporate actions in the recent past.

Mergers and Acquisitions

• In January 2020, the Board of Directors of the company allowed the merger of its wholly-owned subsidiary, Vivimed Life Sciences Pvt Ltd (Vivimed) into the Company.
• In September 2019, Strides Pharma Global Pte. Limited (SPG), a step-down subsidiary in Singapore, acquired a 70% equity stake in Fairmed Healthcare AG (Fairmed), a Switzerland-based generic pharma company.
• In FY 2016, the company acquired the erstwhile Ranbaxy’s Solus’ and Solus Care’ divisions which were operating in the Central Nervous System (CNS) segment in India from Sun Pharmaceuticals Limited.